CN Bio targets US growth as Parisi agrees to head Stateside strategy

Cambridge-based CN Bio Ltd, a leading Organ-on-a-Chip company that designs and manufactures single and multi-organ microphysiological systems (MPS), has appointed Joseph Parisi as US Director of Sales.

Parisi will lead the expansion of the company’s sales and support activities for the US market to address the growing demand for new alternative methodologies in preclinical drug discovery.

Following several key senior hires in the UK last year, Parisi’s appointment will strengthen CN Bio’s growth in another of its key markets, providing a local source of expertise and support for customers looking to harness the company’s PhysioMimix® OOC range of MPS.

Over the past year, the global demand for NAMs has accelerated, particularly in the US following the enactment of the FDA Modernization Act 2.01.

Parisi’s sales expertise will be crucial for meeting this growing demand, working alongside the leadership team to drive the commercial expansion strategy whilst supporting customers to improve the human relevance of preclinical workflows and reduce animal model reliance.

Parisi holds a strong track record in delivering successful sales strategies across the biotechnology sector. He joins from Phenomix (acquired by Bruker Corporation in 2023), where he was Director of Sales for US West and led an experienced team responsible for growing the proteomics side of the business.

At Purigen Biosystems (acquired by Bionano Genomics in 2022), he was Director of West Coast Sales, overseeing commercial development, supporting the company’s growth from startup to commercial success over three years.

Additionally, he has held senior roles at numerous life sciences organisations including Isoplexis, NanoString Technologies and Life Technologies.

Parisi says: “The potential offered by CN Bio’s PhysioMimix range, substantiated by the company’s collaborative work with the FDA, is truly transformative for the drug discovery industry, providing clinical translatability that can improve efficiency and minimise drug failures.”

CEO Dr Paul Brooks added: “Joe’s appointment represents an important milestone in CN Bio’s growth, having successfully built a strong international presence and now looking to expand this further into the US – a key market for innovative drug discovery.”